SA
ARTV

Sanctuary Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

Sanctuary Advisors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,581
Closed -$139K – 2941
2026
Q1 		$139K Buy
+21,581
New +$107K ﹤0.01% 2423

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Sanctuary Advisors's ARTV Position: Q2 2026 in Review

Sanctuary Advisors sold out of Artiva Biotherapeutics (ARTV) in Q2 2026, closing a stake of 21,581 shares — an estimated $139K sold.

Sanctuary Advisors first reported a position in ARTV in Q1 2026 and held it in 1 quarter. The position peaked at $139K in Q1 2026. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Sanctuary Advisors reported no remaining Artiva Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Sanctuary Advisors sold 21,581 Artiva Biotherapeutics shares in Q2 2026, an estimated $139K.
  • Sanctuary Advisors first reported a position in Artiva Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Sanctuary Advisors's Artiva Biotherapeutics position peaked at $139K in Q1 2026.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.